These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19681119)

  • 1. RAS signaling dysregulation in human embryonal Rhabdomyosarcoma.
    Martinelli S; McDowell HP; Vigne SD; Kokai G; Uccini S; Tartaglia M; Dominici C
    Genes Chromosomes Cancer; 2009 Nov; 48(11):975-82. PubMed ID: 19681119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
    Ohashi K; Sequist LV; Arcila ME; Moran T; Chmielecki J; Lin YL; Pan Y; Wang L; de Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; Yang JC; Miller VA; Riely GJ; Kris MG; Engelman JA; Vnencak-Jones CL; Dias-Santagata D; Ladanyi M; Pao W
    Proc Natl Acad Sci U S A; 2012 Jul; 109(31):E2127-33. PubMed ID: 22773810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic and survival correlates of embryonal rhabdomyosarcoma driven by RAS/RAF mutations.
    Agaram NP; Huang SC; Tap WD; Wexler LH; Antonescu CR
    Genes Chromosomes Cancer; 2022 Mar; 61(3):131-137. PubMed ID: 34755412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
    Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
    Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
    Chen Y; Takita J; Hiwatari M; Igarashi T; Hanada R; Kikuchi A; Hongo T; Taki T; Ogasawara M; Shimada A; Hayashi Y
    Genes Chromosomes Cancer; 2006 Jun; 45(6):583-91. PubMed ID: 16518851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.
    Nishimura R; Takita J; Sato-Otsubo A; Kato M; Koh K; Hanada R; Tanaka Y; Kato K; Maeda D; Fukayama M; Sanada M; Hayashi Y; Ogawa S
    Cancer Sci; 2013 Jul; 104(7):856-64. PubMed ID: 23578105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders.
    Nyström AM; Ekvall S; Berglund E; Björkqvist M; Braathen G; Duchen K; Enell H; Holmberg E; Holmlund U; Olsson-Engman M; Annerén G; Bondeson ML
    J Med Genet; 2008 Aug; 45(8):500-6. PubMed ID: 18456719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene.
    Schaaf G; Hamdi M; Zwijnenburg D; Lakeman A; Geerts D; Versteeg R; Kool M
    Cancer Res; 2010 Jan; 70(2):762-71. PubMed ID: 20068162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
    Nava C; Hanna N; Michot C; Pereira S; Pouvreau N; Niihori T; Aoki Y; Matsubara Y; Arveiler B; Lacombe D; Pasmant E; Parfait B; Baumann C; Héron D; Sigaudy S; Toutain A; Rio M; Goldenberg A; Leheup B; Verloes A; Cavé H
    J Med Genet; 2007 Dec; 44(12):763-71. PubMed ID: 17704260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive profile of disorders associated with dysregulation of the RAS/MAPK signaling cascade.
    Cesarini L; Alfieri P; Pantaleoni F; Vasta I; Cerutti M; Petrangeli V; Mariotti P; Leoni C; Ricci D; Vicari S; Selicorni A; Tartaglia M; Mercuri E; Zampino G
    Am J Med Genet A; 2009 Feb; 149A(2):140-6. PubMed ID: 19133693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.
    Seki M; Nishimura R; Yoshida K; Shimamura T; Shiraishi Y; Sato Y; Kato M; Chiba K; Tanaka H; Hoshino N; Nagae G; Shiozawa Y; Okuno Y; Hosoi H; Tanaka Y; Okita H; Miyachi M; Souzaki R; Taguchi T; Koh K; Hanada R; Kato K; Nomura Y; Akiyama M; Oka A; Igarashi T; Miyano S; Aburatani H; Hayashi Y; Ogawa S; Takita J
    Nat Commun; 2015 Jul; 6():7557. PubMed ID: 26138366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zebrafish models of rhabdomyosarcoma.
    Chen EY; Langenau DM
    Methods Cell Biol; 2011; 105():383-402. PubMed ID: 21951539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
    Shukla N; Ameur N; Yilmaz I; Nafa K; Lau CY; Marchetti A; Borsu L; Barr FG; Ladanyi M
    Clin Cancer Res; 2012 Feb; 18(3):748-57. PubMed ID: 22142829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome.
    Narumi Y; Aoki Y; Niihori T; Neri G; Cavé H; Verloes A; Nava C; Kavamura MI; Okamoto N; Kurosawa K; Hennekam RC; Wilson LC; Gillessen-Kaesbach G; Wieczorek D; Lapunzina P; Ohashi H; Makita Y; Kondo I; Tsuchiya S; Ito E; Sameshima K; Kato K; Kure S; Matsubara Y
    Am J Med Genet A; 2007 Apr; 143A(8):799-807. PubMed ID: 17366577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.
    Case M; Matheson E; Minto L; Hassan R; Harrison CJ; Bown N; Bailey S; Vormoor J; Hall AG; Irving JA
    Cancer Res; 2008 Aug; 68(16):6803-9. PubMed ID: 18701506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
    Schulz AL; Albrecht B; Arici C; van der Burgt I; Buske A; Gillessen-Kaesbach G; Heller R; Horn D; Hübner CA; Korenke GC; König R; Kress W; Krüger G; Meinecke P; Mücke J; Plecko B; Rossier E; Schinzel A; Schulze A; Seemanova E; Seidel H; Spranger S; Tuysuz B; Uhrig S; Wieczorek D; Kutsche K; Zenker M
    Clin Genet; 2008 Jan; 73(1):62-70. PubMed ID: 18042262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NRAS associated RASopathy and embryonal rhabdomyosarcoma.
    Garren B; Stephan M; Hogue JS
    Am J Med Genet A; 2020 Jan; 182(1):195-200. PubMed ID: 31697451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling.
    Haling JR; Sudhamsu J; Yen I; Sideris S; Sandoval W; Phung W; Bravo BJ; Giannetti AM; Peck A; Masselot A; Morales T; Smith D; Brandhuber BJ; Hymowitz SG; Malek S
    Cancer Cell; 2014 Sep; 26(3):402-413. PubMed ID: 25155755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.
    Andrews MC; Behren A; Chionh F; Mariadason J; Vella LJ; Do H; Dobrovic A; Tebbutt N; Cebon J
    J Clin Oncol; 2013 Dec; 31(35):e448-51. PubMed ID: 24190114
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.